Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

After [losing out to Pfizer]( ...

Pharmaceutical giant Pfizer has finally acquired development-stage obesity drugmaker Metsera Inc., in an intense bidding war against the Danish drugmaker Novo Nordisk for over $10 billion.

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Indiana's harvest nears completion, Pfizer acquires weight-loss drug company, YouTube TV issues refunds, and Starbucks ...

Here are some of the stocks making notable moves in Monday's premarket action: TreeHouse Foods shares are surging 19% after the food and beverage company agreed to be taken private by Industrial F&B ...